


AMENDMENTS TO THE CLAIMS

This listing of claims replaces any prior version of the claims in the application.

5 Claims 1-32 (cancelled)

33 (withdrawn): A pharmaceutical composition comprising at least one compound of the following structure



10 wherein R⁵ and R⁶ are each independently selected from the group consisting of OC(O)OCH₃, -OH, -SH, -NH₂, -OSO₃H, -OPO₃H, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer, provided that at least one of R⁷ and R⁸
15 are OC(O)OCH₃;
20

 wherein R⁷, R⁸, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ are each independently selected from the group consisting of -H, -OH, -SH, -NH₂, -OSO₃H, -OPO₃H, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether,

an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer and R^7 and R^8 together, R^{12} and R^{13} together, R^{14} and R^{15} together, R^{16} and R^{17} together, and R^{18} and R^{19} together independently form a double bond to a moiety selected from the group consisting of $=O$, $=S$, $=CH_2$ and $=NOH$, provided that only one each of R^{12} and R^{13} or R^{18} and R^{19} can independently be H;


wherein R^{24} and R^{25} are either H or CH_3 ;

wherein the dotted line is an optional double bond;

wherein the $OC(O)OCH_3$ at the 3 position is in either the α or β configuration;

and a pharmaceutically acceptable excipient.

34 (withdrawn): The pharmaceutical composition of claim 33, wherein said at least one compound has the following structure



wherein R^7 , R^8 , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} and R^{19} are each independently selected from the group consisting of $-H$, $-OH$, $-SH$, $-NH_2$, $-OSO_3H$, $-OPO_3H$, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally


substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a
5 nucleoside, a nucleotide, an oligonucleotide, a polymer and R^7 and R^8 together, R^{12} and R^{13} together, R^{14} and R^{15} together, R^{16} and R^{17} together, and R^{18} and R^{19} together independently form a double bond to a moiety selected from the group consisting of $=O$, $=S$, $=CH_2$ and $=NOH$, provided that only one each of R^{12} and R^{13} or R^{18} and R^{19} can independently be H;

10 wherein R^{24} and R^{25} are either H or CH_3 ;

wherein the dotted line is an optional double bond;

wherein the $OC(O)OCH_3$ at the 3 position is in either the α or β configuration; and a pharmaceutically acceptable excipient.


15 35 (withdrawn): The pharmaceutical composition of claim 34, wherein said at least one compound has the following structure



wherein R^7 , R^8 , R^{12} , R^{13} , R^{14} , R^{15} , R^{16} and R^{17} are each independently selected from the group consisting of -H, -OH, -SH, - NH_2 , - OSO_3H , - OPO_3H , an ester, a
20 phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle,

an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer and R^7 and R^8 together, R^{12} and R^{13} together, R^{14} and R^{15} together, and R^{16} and R^{17} together independently form a double bond to a moiety selected from the group consisting of $=O$, $=S$, $=CH_2$ and $=NOH$, provided that only one of each of R^{12} and R^{13} can independently be H; wherein R^{24} and R^{25} are either H or CH_3 ; wherein the dotted line is an optional double bond; wherein the $OC(O)OCH_3$ at the 3 position is in either the α or β configuration; and a pharmaceutically acceptable excipient.

36 (withdrawn): The pharmaceutical composition of claim 35, wherein said at least one compound has the following structure



wherein R^{12} and R^{13} are each independently selected from the group consisting of -H, -OH, -SH, $-NH_2$, $-OSO_3H$, $-OPO_3H$, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a nucleotide, an oligonucleotide, a polymer and R^{12} and R^{13} together form a double


bond to a moiety selected from the group consisting of =O, =S, =CH₂ and =NOH, provided that only one of R¹² and R¹³ is H;

wherein R²⁴ and R²⁵ are either H or CH₃;

wherein the dotted line is an optional double bond;

- 5 wherein the OC(O)OCH₃ at the 3 position is in either the α or β configuration; and a pharmaceutically acceptable excipient.

37 (withdrawn): The pharmaceutical composition of claim 34, wherein said at least one compound has the following structure




10 wherein R⁷, R⁸, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸ and R¹⁹ are each independently selected from the group consisting of -H, -OH, -SH, -NH₂, -OSO₃H, -OPO₃H, an ester, a phosphoester, a phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a sulfonamide, an amino acid, an ether, a thioether, an acyl
15 group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted aryl moiety, an optionally substituted heterocycle, an optionally substituted heteroaryl moiety, an optionally substituted monosaccharide, an optionally substituted oligosaccharide, a
20 nucleoside, a nucleotide, an oligonucleotide, a polymer and R⁷ and R⁸ together, R¹⁴ and R¹⁵ together, R¹⁶ and R¹⁷ together, and R¹⁸ and R¹⁹ together independently form a double bond to a moiety selected from the group consisting of =O, =S, =CH₂ and =NOH, provided that only one of each of R¹⁸ and R¹⁹ can be H;

wherein R^{24} and R^{25} are either H or CH_3 ;
wherein the dotted line is an optional double bond;
wherein the $OC(O)OCH_3$ at the 3 position is in either the α or β
configuration; and a pharmaceutically acceptable excipient.

5

38 (withdrawn): The pharmaceutical composition of claim 37, wherein said
at least one compound has the following structure




wherein R^{18} and R^{19} are each independently selected from the group
consisting of -H, -OH, -SH, - NH_2 , - OSO_3H , - OPO_3H , an ester, a phosphoester, a
phosphonoester, a sulfite ester, a sulfate ester, a thioester, an amide, a
sulfonamide, an amino acid, an ether, a thioether, an acyl group, a carbonate, a
carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an
optionally substituted alkenyl group, an optionally substituted alkynyl group, an
optionally substituted aryl moiety, an optionally substituted heterocycle, an
optionally substituted heteroaryl moiety, an optionally substituted
monosaccharide, an optionally substituted oligosaccharide, a nucleoside, a
nucleotide, an oligonucleotide, a polymer and R^{18} and R^{19} together form a double
bond to a moiety selected from the group consisting of $=O$, $=S$, $=CH_2$ and $=NOH$,
provided that only one of R^{18} and R^{19} is -H;

wherein R^{24} and R^{25} are either H or CH_3 ;
wherein the dotted line is an optional double bond;
wherein the $-OC(O)OCH_3$ at the 3 position is in either the α or β
configuration; and a pharmaceutically acceptable excipient.

25

39 (withdrawn): The pharmaceutical composition of claim 34, wherein said at least one compound has the following structure




and a pharmaceutically acceptable excipient.

5

Claims 40-55 (cancelled)

Claim 56 (currently amended): A method to treat a condition selected from the group consisting of androgen responsive prostate cancer and androgen responsive benign prostatic hyperplasia in a subject, or to ameliorate one or more symptoms thereof, comprising administering to the subject, or delivering to the subject's tissues an effective amount of a compound having the structure



wherein,

R⁵ and R⁶ independently are -H, a carbonate, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, a monosaccharide or an oligosaccharide, provided that R⁵ or R⁶ is a carbonate;

R¹², R¹³, R¹⁶ and R¹⁷ together or each independently are -H, -OR^{PR}, -SR^{PR}, -N(R^{PR})₂, -OSO₃H, -OPO₃H, =O, =S, =CH₂, =NOH, an ester, an amide, an

amino acid, a peptide, an ether, a thioether, an acyl group, a carbonate, a carbamate, a sulfonamide, a halogen, an optionally substituted alkyl group, an optionally substituted alkenyl group or an optionally substituted alkynyl group; and

5 R^{18} and R^{19} together or each independently are -H, -OR^{PR}, -SR^{PR}, -N(R^{PR})₂, =O, =S, =CH₂, =NOH, an ester, an amino acid, a peptide, an ether, a thioether, a carbonate, a carbamate, an optionally substituted alkyl group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, a monosaccharide or an oligosaccharide, provided that R^{18} or R^{19} is -OR^{PR}, -SR^{PR},
10 -N(R^{PR})₂, =O, =S, =NOH, an ester, an amino acid, a peptide, an ether, a thioether, a carbonate, a carbamate, a monosaccharide or an oligosaccharide;


R^{25} is -H or optionally substituted alkyl; and

R^{PR} independently or together are -H or a protecting group, wherein any substituted alkyl, alkenyl or alkynyl moiety contains 1, 2, 3 or 4 independently
15 chosen moieties selected from the group consisting of -O-, -S-, -NR^{PR}-, -C(O)-, -N(R^{PR})₂-, -C(O)OR^{PR}-, -OC(O)R^{PR}-, -OR^{PR}-, -SR^{PR}-, -NO₂-, -CN-, -NHC(O)-, -C(O)NH-, -OC(O)-, -C(O)O-, -O-A8, -S-A8, -C(O)-A8, -OC(O)-A8, -C(O)O-A8, =N-, -N=, -OPO₂R^{PR}-, -OSO₃H-, -F-, -Cl-, -Br and -I, wherein A8 is C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, C₁₋₄ alkyl-aryl, aryl or C₁₋₄ alkyl-C₁₋₅ heterocycle.

20

 Claim 57. (previously presented): The method of claim 56, wherein the condition is androgen responsive prostate cancer.

 Claim 58 (currently amended): The method of claim 57 wherein the
25 compound has the structure



Claim 59 (currently amended): The method of claim 58 wherein

- (a) R¹⁸ is -OH, -O-C(O)-CH₃ or -O-C(O)-CH₂CH₃ and R¹⁹ is -H, -C≡CH or -C≡CCH₃, or R¹⁸ and R¹⁹ together are =O, =S or =NOH, or
5 (b) R¹⁸ is -H, -C≡CH or -C≡CCH₃ and R¹⁹ is -OH, -O-C(O)-CH₃, -O-C(O)-CH₂CH₃.

Claim 60 (canceled)

10 Claim 61 (currently amended): The method of claim 59 wherein R¹² and R¹³ independently or together are -H, -OH, -SH, -NH₂, =CH₂, =CHCH₃, =NOH, =NOC(O)CH₃, =O or =S.

15 Claim 62 (canceled)

20 Claim 63 (previously presented): The method of claim 59 wherein R¹⁶ and R¹⁷ independently or together are -H, -OH, -SH, =O, =S, -O-C(O)-CH₃ or -O-C(O)-OCH₃.

Claim 64 (previously presented): The method of claim 59 wherein R⁵ or R⁶ is -H, -CCH₃, -CH₃ or -C₂H₅.

Claim 65 (previously presented): The method of claim 64 wherein R²⁵ is -
H, -CH₃, -CH₂OH, -CH₂OC(O)CH₃, -OC(O)CH₃ or -CH₂OC(O)OCH₃.

Claim 66 (canceled)

5

Claim 67 (previously presented): The method of claim 65 wherein R²⁵ is -
CH₃.

Claim 68 (previously presented): The method of claim 67 wherein a
10 double bond is present at the 1-2 and 5-6 positions.

Claim 69 (previously presented): The method of claim 67 wherein a
double bond is present at the 5-6 position.

15